Q2 2024 EPS Estimates for Bruker Co. Reduced by Leerink Partnrs (NASDAQ:BRKR)

Bruker Co. (NASDAQ:BRKR) – Stock analysts at Leerink Partnrs dropped their Q2 2024 earnings per share (EPS) estimates for Bruker in a research report issued on Thursday, May 2nd. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $0.54 per share for the quarter, down from their previous estimate of $0.59. The consensus estimate for Bruker’s current full-year earnings is $2.82 per share. Leerink Partnrs also issued estimates for Bruker’s Q3 2024 earnings at $0.78 EPS, Q4 2024 earnings at $0.98 EPS, FY2024 earnings at $2.83 EPS, Q1 2025 earnings at $0.63 EPS, Q2 2025 earnings at $0.72 EPS, Q3 2025 earnings at $0.90 EPS, Q4 2025 earnings at $1.20 EPS and FY2026 earnings at $4.02 EPS.

A number of other equities research analysts also recently weighed in on BRKR. The Goldman Sachs Group raised their price target on Bruker from $66.00 to $74.00 and gave the company a “sell” rating in a research report on Wednesday, April 10th. Citigroup boosted their target price on Bruker from $80.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th. JPMorgan Chase & Co. raised Bruker from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $60.00 to $90.00 in a research note on Wednesday, February 14th. Stifel Nicolaus lifted their price target on shares of Bruker from $63.00 to $81.00 and gave the stock a “hold” rating in a research note on Wednesday, February 14th. Finally, UBS Group boosted their price objective on shares of Bruker from $94.00 to $102.00 and gave the stock a “buy” rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $84.86.

Bruker Stock Up 3.5 %

Shares of NASDAQ:BRKR opened at $72.52 on Monday. The firm has a market capitalization of $10.54 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 1.73 and a beta of 1.22. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.91 and a current ratio of 1.81. Bruker has a 52-week low of $53.79 and a 52-week high of $94.86. The firm has a fifty day moving average of $87.16 and a 200 day moving average of $75.34.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. The business had revenue of $721.70 million during the quarter, compared to analysts’ expectations of $729.88 million. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.64 EPS.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Friday, March 1st were paid a dividend of $0.05 per share. The ex-dividend date was Thursday, February 29th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.28%. Bruker’s dividend payout ratio (DPR) is currently 7.27%.

Insider Activity

In other news, Director Hermann Fritz Requardt sold 15,000 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the transaction, the director now directly owns 23,147 shares of the company’s stock, valued at $2,084,618.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 28.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of BRKR. Norges Bank purchased a new stake in shares of Bruker during the fourth quarter worth about $74,582,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of Bruker by 8.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 7,840,735 shares of the medical research company’s stock worth $488,478,000 after purchasing an additional 594,362 shares during the period. TD Asset Management Inc boosted its holdings in shares of Bruker by 51.1% during the fourth quarter. TD Asset Management Inc now owns 1,664,779 shares of the medical research company’s stock worth $122,328,000 after purchasing an additional 562,684 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Bruker by 95.2% during the third quarter. Ameriprise Financial Inc. now owns 928,418 shares of the medical research company’s stock worth $57,840,000 after purchasing an additional 452,780 shares during the period. Finally, RTW Investments LP boosted its holdings in shares of Bruker by 14.3% during the third quarter. RTW Investments LP now owns 3,381,703 shares of the medical research company’s stock worth $210,680,000 after purchasing an additional 422,100 shares during the period. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.